VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

15 A EGIS C APITAL C ORP. Major Depressive Disorder (“MDD”) Depression, or Major Depressive Disorder, or MDD, is a mood disorder characterized by feelings of sadness, and loss of interest. According to The Mayo Clinic, depression is not simply a “case of the blues” from which patients can simply “snap out,” but, rather, a condition that may require long-term treatment. Treatment may include medication (see more in the section on competition) and psychotherapy, among other types of treatment. 7 Symptoms of MDD are known to include: sadness, tearfulness, emptiness, hopelessness, angry outbursts, irritability, frustration, lack of interest or pleasure, sleep disturbances, or sleeping too much, tiredness, lack of energy, changes in appetite, weight, food cravings, anxiety, agitation, restlessness, slowed thinking, speaking, or body movements, and others. Other symptoms can include trouble thinking, concentrating, feelings of worthlessness or guilt, fixating on past failures, self-blame, and physical problems such as back pain or headaches. 7 Incidence of MDD in the U.S. is significant. According to the National Institute of Mental Health, an estimated 17.3mm adults in the U.S. had at least one major depressive episode in the past year. MDD disproportionately impacts females (8.7%) than males (5.3%). 10 CNS indications Here, we point out briefly some of the CNS indications that could become a target for development now and in the future, given VistaGen’s current portfolio, and these include neuropathic pain, Levodopa-induced Dyskinesia (LID) associated with Parkinson’s Therapy, Epilepsy, and Suicidal ideation. 2 VistaGen Therapeutics, Inc. October 8, 2020